首页> 外文期刊>Vaccine >Evaluation of hyaluronic acid-based combination adjuvant containing monophosphoryl lipid A and aluminum salt for hepatitis B vaccine
【24h】

Evaluation of hyaluronic acid-based combination adjuvant containing monophosphoryl lipid A and aluminum salt for hepatitis B vaccine

机译:含单磷酰脂质A和铝盐的透明质酸基复合佐剂对乙肝疫苗的评价

获取原文
获取原文并翻译 | 示例
           

摘要

Here, monophosphoryl lipid A (MPLA) and aluminum salt (Alum) were introduced into a hyaluronic acid (HA)-based combination vaccine adjuvant for hepatitis B vaccine (HBV). Although Alum is a well-known hepatitis B vaccine adjuvant that induces an enhanced humoral immune response, it cannot induce the cellular immune responses. On the other hand, MPLA has been generally reported to promote IFN-gamma production via antigen-specific CD4(+) T cells, but it is not water soluble as a result of its long hydrophobic alkyl chains. To this end, water insoluble MPLA could be solubilized in an aqueous solution with the help of HA, which contains many carboxyl and hydroxyl groups that can be used to attach to the hydroxyl head groups of MPLA via hydrogen bonds. Three groups of mice were treated with either hepatitis B surface antigen (HBsAg) alone, HBsAg_Alum complex, or HBsAg_Alum_MPLA/HA complex. The group immunized with the HBsAg_Alum_MPLA/HA complex exhibited a high increase in cellular immune response as well as in humoral immune response relative to the other two groups. The antibody, cytokine and T cell levels were most elevated in the group of mice immunized with HBsAg_Alum_MPLA/HA complex, even at a 1 mu g/mice dose, and the magnitude was still maintained even after 8 weeks. Specifically, the antibody value was 120 times larger in mice vaccinated with HBsAg_Alum_MPLA/HA complex than in mice vaccinated with HBsAg_Alum complex designed similar to commercially available hepatitis B vaccine, Engerix B. The cytokine and T cell proliferation levels were 2 times and 6 times larger in mice adjuvanted with HBsAg_Alum_MPLA/HA complex than in those vaccinated with HBsAg_Alum. The results therefore indicate that incorporating MPLA and Alum with HA can be a potent strategy to increase both the magnitude and the persistence of HBsAg-specific immune responses to protect hosts against hepatitis B virus infection. (C) 2015 Elsevier Ltd. All rights reserved.
机译:在这里,将单磷酰脂质A(MPLA)和铝盐(明矾)引入到基于透明质酸(HA)的乙肝疫苗(HBV)组合疫苗佐剂中。尽管明矾是一种众所周知的B型肝炎疫苗佐剂,可诱导增强的体液免疫反应,但它不能诱导细胞免疫反应。另一方面,据报道,MPLA可通过抗原特异性CD4(+)T细胞促进IFN-γ的产生,但由于其较长的疏水性烷基链,因此不溶于水。为此,可以在HA的帮助下将水不溶性MPLA溶解在水溶液中,该HA含有许多羧基和羟基,可用于通过氢键连接到MPLA的羟基头基上。三组小鼠分别用乙型肝炎表面抗原(HBsAg),HBsAg_Alum复合物或HBsAg_Alum_MPLA / HA复合物治疗。相对于其他两组,用HBsAg_Alum_MPLA / HA复合物免疫的组显示出细胞免疫应答以及体液免疫应答的高度增加。在以HBsAg_Alum_MPLA / HA复合物免疫的小鼠组中,即使以1μg/小鼠的剂量免疫,其抗体,细胞因子和T细胞水平也最高,并且即使在8周后仍能保持其大小。具体来说,接种HBsAg_Alum_MPLA / HA复合物的小鼠的抗体值比接种HBsAg_Alum复合物的小鼠(设计类似于市售乙型肝炎疫苗Engerix B)大120倍。细胞因子和T细胞增殖水平分别是2倍和6倍与HBsAg_Alum_MPA / HA复合物佐剂的小鼠相比,HBsAg_Alum_MPLA / HA复合物佐剂的小鼠的比例要高。因此,结果表明,将MPLA和明矾与HA结合使用可以有效提高HBsAg特异性免疫反应的强度和持久性,从而保护宿主免受乙型肝炎病毒感染。 (C)2015 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号